Analyst Price Targets — JSPR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 9, 2025 11:19 am | Gregory Renza | RBC Capital | $48.00 | $17.71 | TheFly | Jasper Therapeutics price target lowered to $48 from $68 at RBC Capital |
| December 5, 2024 9:06 pm | Etzer Darout | BMO Capital | $63.00 | $21.53 | StreetInsider | BMO Capital Starts Jasper Therapeutics (JSPR) at Outperform |
| May 6, 2024 6:06 am | Emily Bodnar | H.C. Wainwright | $65.00 | $24.52 | StreetInsider | H.C. Wainwright Starts Jasper Therapeutics (JSPR) at Buy, "an underappreciated gem in the autoimmune and inflammatory disease space" |
| April 3, 2024 6:38 am | Gavin Clark-Gartner | Evercore ISI | $65.00 | $26.20 | StreetInsider | Evercore ISI Starts Jasper Therapeutics (JSPR) at Outperform |
| February 7, 2023 7:38 am | — | Cantor Fitzgerald | $6.00 | $1.92 | Benzinga | Cantor Fitzgerald Reiterates Overweight on Jasper Therapeutics, Lowers Price Target to $6 |
| January 11, 2023 8:08 am | — | Credit Suisse | $3.00 | $1.65 | Benzinga | Credit Suisse Maintains Outperform on Jasper Therapeutics, Lowers Price Target to $3 |
Latest News for JSPR
REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter and year…
Pre-Market Stock Futures: Futures are trading higher after President Trump signalled that talks with Iran are progressing positively, as we get ready to start another trading week, with the same issues that have dragged the stock market down for four consecutive weeks still in place. While we have had a virtual March Madness in stocks,... Here Are Monday's Top Wall Street Analyst Research Calls: APA Corporation,…
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate at the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for JSPR.
U.S. House Trading
No House trades found for JSPR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.